VEGF production by cancer cells, and to a lesser degree by tumor stromal cells, is crucial to tumorigenesis progression 49; anti-VEGF agents such as bevacizumab, a humanized monoclonal antibody directed against VEGF, have been successfully used to treat various human cancers, especially colon cancer 1,51–55. This evidence concerns the gene VEGFA and malignant colon neoplasm.